Relypsa (RLYP): Veltassa's Path To Preferred Hyperkalemia Treatment - Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Relypsa's (RLYP) Veltassa Expected to Benefit from Delay to AstraZeneca's (AZN) ZS-9 - BTIG
June 2, 2016 7:47 AM EDTBTIG affirms Relypsa (Nasdaq: RLYP) at Buy with a price target of $35 following recent conversations with management.
Analyst Timothy Chiang commented, We recently hosted a Q&A session with Relypsas senior management team to discuss a number of key items including the recent CRL... More
Mizuho Securities Upgrades Relypsa (RLYP) to Neutral; Strengthened Veltassa Launch and Higher Probability of a Takeout
June 1, 2016 6:18 AM EDTMizuho Securities upgraded Relypsa, Inc. (NASDAQ: RLYP) from Underperform to Neutral with a price target of $20.00 (from $12.00).
Analyst Irina Koffler commented, "Relypsa's stock is benefiting from a regulatory delay of competitor AZN, which gives Relypsa more time to strengthen its Veltassa launch and explore strategic alternatives. With the recent run-up, we believe shares are fairly valued and upgrade the stock to Neutral from... More
